Candel Targets Mid-2027 Prostate-Cancer Application With Assay Work Still Shaping Its Timing

The cancer-treatment developer expects its $203.1 million cash balance to support operations into the second quarter of 2028.

Share
Candel Targets Mid-2027 Prostate-Cancer Application With Assay Work Still Shaping Its Timing

Candel Therapeutics, which is developing aglatimagene for prostate cancer, plans to seek FDA approval in the middle of 2027, with assay-refinement work and discussions with the agency shaping that timetable. Its earnings release accompanying Thursday's SEC filing put cash at $203.1 million at September 30—money management expects to fund its current operating plan into the second quarter of 2028.

Building Toward A Prostate-Cancer Launch

Candel is preparing the clinical and manufacturing portions of its approval application. Its manufacturing contractor has completed process-validation production, and the resulting batches are being tested for intended commercial use if aglatimagene wins approval. Clinical supplies have also been produced with the new process.

The company uses engineered viruses injected into tumors to stimulate an immune response against cancer. Aglatimagene comes from its modified adenovirus platform; linoserpaturev, being tested against recurrent high-grade glioma, a brain tumor, uses modified herpes simplex virus.

Candel appointed Martine Zimmermann to its board in September and announced Maria Ostrovsky's appointment as general counsel in October, effective November 3. Zimmermann has more than 30 years of regulatory and quality experience; Ostrovsky brings 20 years of legal experience and contributed to two global product launches at Deciphera Pharmaceuticals.

President and CEO Paul Peter Tak said their expertise is relevant “as we prepare for BLA submission and potential future launch.” BLA is the FDA approval application for a biological treatment.

The Clinical Case Behind Aglatimagene

Candel previously reported negative prostate biopsies two years after treatment in 80% of evaluable aglatimagene patients, compared with 63% of controls. Those groups included 167 and 62 patients, respectively.

On Friday, the company presented additional immune-response data, including increases in cancer-fighting T cells after treatment. Candel said the findings help inform its planned application and support its explanation of the systemic effects seen in the completed late-stage prostate-cancer trial.

Aglatimagene is also in a late-stage trial for metastatic non-squamous non-small cell lung cancer that has progressed despite pembrolizumab and platinum-based chemotherapy. The study compares an aglatimagene combination with docetaxel chemotherapy, with overall survival as its main goal.

Updated early-stage linoserpaturev results showed median survival of 12.0 months in the 50-patient cohort. In the repeated-treatment cohort of 12 patients, median survival was 14.3 months, but Candel cautioned that those survival data remain immature.

Trial And Launch Preparations Cost More

Third-quarter research spending rose to $15.6 million from $8.5 million a year earlier. Candel attributed the increase primarily to aglatimagene trial and manufacturing costs and employee expenses. Non-cash stock pay within that spending increased to $1.0 million from $0.5 million.

Administrative spending reached $7.4 million, compared with $4.7 million a year earlier. The company attributed that increase mainly to employee costs and preparations for potential commercialization; included non-cash stock pay rose to $1.7 million from $0.6 million.

The quarterly net loss widened to $21.9 million from $11.3 million, or $0.28 per share versus $0.21. Net other income fell to $1.1 million from $1.9 million, which Candel attributed primarily to higher interest expense, partly offset by increased interest income.

Cash and equivalents stood at $203.1 million at September 30, compared with $119.7 million at December 31, 2025.

Candel's next planned regulatory milestone is the mid-2027 application, pending the outcome of its FDA discussions. The validation batches now under testing are intended for commercial use only if approval follows.

Sources

More on Candel Therapeutics

All Candel Therapeutics (CADL) coverage →